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OBJECTIVE — Osteocalcin (OC), a bone-derived protein, was recently shown to regulate
metabolic pathways in mice. Undercarboxylated OC (ucOC), but not carboxylated OC (cOC),
increases adiponectin and insulin secretion. It is unclear if carboxylation of OC affects its
association with metabolic parameters in humans.
RESEARCH DESIGN AND METHODS — The associations between ucOC, cOC, total
and high-molecular-weight (HMW) adiponectin, and insulin secretion (homeostasis model as-
sessment [HOMA]-) were investigated in a population-based sample of healthy prepubertal
children (n  103; 49 boys and 54 girls).
RESULTS — Weight-dependent associations were observed between the different forms of
OC and metabolic parameters. Higher cOC was related to lower HMW adiponectin (with a
stronger association in leaner children; P  0.001). Higher ucOC-to-cOC ratio was associated
with higher HOMA- (P  0.01) in leaner children and associated with higher HMW adiponec-
tin (P  0.001) in heavier children.
CONCLUSIONS — In a weight-dependent manner, cOC and the proportion of ucOC are
differentially related to HMW adiponectin and insulin secretion in healthy children.
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T
here is feedback between glucose
and bone metabolism (1). Adi-
ponectin, a protein secreted by the
adipose tissue with insulin-sensitizing
and anti-atherosclerotic properties (2),
has emerged as an element in the regula-
tionofbonemass(3).Recentstudieshave
closed this feedback by revealing a direct
regulation of metabolic pathways by the
skeleton through osteocalcin (OC) pro-
duction (4).
Osteocalcin, an osteoblast product, is
the most abundant noncollagenous pro-
tein of bone matrix and a long-known pa-
rameter of bone formation (5). The
protein is subjected to posttranslational
carboxylation by a vitamin K–dependent
carboxylase to yield carboxylated (cOC)
and undercarboxylated (ucOC) mole-
cules. cOC has higher afﬁnity for hy-
droxyapatite and is thought to be the
active form in the bone (5).
Recent studies have disclosed that
ucOC,butnotcOC,iscapableofenhanc-
ing adiponectin and insulin secretion in
mice (4,6); clinical studies have shown
independent associations between circu-
lating total OC and metabolic traits in
adult populations (7–10). However, it is
currently unclear which of the carboxy-
lated forms of OC is associated with me-
tabolism in humans.
We investigated the clinical associa-
tions between both serum ucOC and
cOC, total and high-molecular-weight
(HMW) adiponectin (because it is un-
known if this fraction of the protein is
related to serum OC), and insulin secre-
tion (homeostasis model assessment
[HOMA]-) in a population-based sam-
ple of healthy children. Our primary hy-
pothesis was that serum ucOC is the
preferred molecular form associated with
adiponectin and insulin secretion. As a
secondary hypothesis, any given associa-
tion between cOC and metabolic param-
eters is a reﬂection of the known
regulation of bone mass by metabolism,
given that 1) cOC is the active form in the
boneand2)cOCdoesnothavemetabolic
effects in vitro or in vivo.
RESEARCH DESIGN AND
METHODS— Subjects were 103
school-age Caucasian children (49 boys
and 54 girls; aged 6.6  0.1 years; sup-
plementary Table 1 in the online appendix,
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc09-1837/DC1) consecu-
tively recruited among children seen at
thepediatricprimarycareclinicsforwell-
child checkup visits in Alt Emporda `, a re-
gion in northern Spain. Inclusion criteria
included age between 5 and 9 years and
absence of puberty. Exclusion criteria
were evidence of acute or chronic illness.
The protocol was approved by the re-
gional Institutional Review Board. In-
formed written consent was obtained
from the parents.
Weight and height were measured
with a calibrated scale and a Harpenden
stadiometer, respectively. Waist circum-
ference was measured at the umbilical
level. Blood pressure was measured with
an electronic sphygmomanometer. Body
composition was assessed by bioelectric
impedance (Hydra Bioimpedance Ana-
lyzer 4200; Xitron Technologies, San Di-
ego, CA).
Fastingserumglucose,lipids,andim-
munoreactive insulin were assayed as de-
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secretion were estimated by the ho-
meostasis model assessment (HOMA–
insulin resistance [IR] and HOMA-
[12]). Total and HMW adiponectin (the
active fraction of the protein) were mea-
suredbysandwichenzyme-linkedimmu-
nosorbentassays(Linco,St.Charles,MO)
(10). Total OC was measured by an en-
zyme immunological test (Nordic Bio-
science Diagnostics, Herlev, Denmark)
with a sensitivity of 0.5 ng/ml, and ucOC
was measured by a solid-phase enzyme
immunoassay (EIA) kit (Glu-OC MK-
118; Takara Bio, Otsu, Shiga, Japan) with
a sensitivity of 0.25 ng/ml. Coefﬁcients of
variationatourlaboratorywere6%.Se-
rum cOC was calculated as the difference
between total and ucOC.
StatisticalanalysesusingSPSSversion
12.0(SPSS,Chicago,IL)consistedofsim-
ple correlation followed by stepwise mul-
tiple regression. ucOC-to-cOC ratio,
rather than ucOC, was used to correct for
theparallelinversechangeincOC.Signif-
icance level was set at P  0.05.
RESULTS— Weight-dependent asso-
ciations were observed between the dif-
ferent forms of OC and metabolic
parameters. Higher cOC was related to
lower HMW adiponectin (with a stronger
association in leaner children; P  0.001;
Fig. 1). Higher ucOC-to-cOC ratio in
leaner children was associated with
higher HOMA- (P  0.01) and in
heavier children associated with higher
HMW adiponectin (P  0.001; Fig. 1).
These associations were either decreased
or absent for total adiponectin.
In multiple regression analyses, both
HMWadiponectin(1.04to1.32;
R
2  0.11–0.20) and BMI (3.06,
R
2  0.07) were independently related to
cOC. In similar analyses, ucOC-to-cOC
ratio (1.58–3.76; R
2  0.04–0.20)
was independently related to HMW adi-
ponectin. Nonpredictive variables were




2  0.08). Nonpredictive variables were
sex, BMI, and fat mass. This association,
however, was apparent in leaner but not
in heavier children.
CONCLUSIONS — Our study de-
ﬁnes the clinical associations between the
different carboxylated forms of OC and
metabolicparametersinhealthychildren.
Recent clinical reports have demon-
strated signiﬁcant associations between
circulating total OC and adiponectin in
adults(7–10,13).Dataregardingtherela-
tion to insulin secretion are scarcer (8).
Despite the fact that most of these studies
did not discern between ucOC and cOC,
the associations were assumed as being
consistent with the purported role of
ucOC regulating adiponectin and insulin
secretion (4). Our results support these
Figure1—Correlationgraphsofbothcarboxylatedosteocalcin(cOsteocalcin)andundercarboxylated-to-carboxylatedosteocalcin(ucOsteocalcin-
to-cOsteocalcin)ratiowithHMWadiponectininhealthychildren(n103)andinsubgroupsaccordingtoaBMIcutoff(beloworabovethemedian).
F and E depict boys and girls, respectively. r and P values are from Pearson analyses.
Osteocalcin and metabolism
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research (4,6) pointing, for the ﬁrst
time, to our knowledge, to an increase
in the relative concentration of ucOC as
being associated with both increased
HMW adiponectin and insulin secre-
tion in humans.
Our ﬁndings also indicate that cOC
(the active form in the bone) is related to
metabolic parameters in humans. The in-
dependentassociationsbetweencOCand
both HMW adiponectin and BMI ﬁt well
with the known regulation of bone mass
by metabolic parameters (14), particu-
larly with the known inverse association
between adiponectin and bone mass (1).
These observations, together with the fact
that adiponectin receptors are expressed
inosteoblasts(15),supportapossiblerole
of HMW adiponectin in the regulation of
OC expression and/or carboxylation,
thereby opening the perspective for an
adiponectin-osteocalcin loop in humans.
Our study ﬁnally suggests different
priorities in the reciprocal regulation of
glucose and bone metabolism depending
on the weight status. The abundance of
HMW adiponectin in leaner subjects may
contributetotherelativeosteopeniacom-
monly observed in these subjects. An in-
crease in the relative proportion in ucOC
maycontributetoimprovedinsulinsecre-
tioninleanersubjectsandcompensatefor
the decrease in HMW adiponectin in
heavier subjects.
In conclusion, in a weight-dependent
manner, carboxylation of OC affects its
association with metabolic parameters in
healthy children.
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